TUMOR REMISSION IN YOSHIDA SARCOMA-BEARING RATS BY SELECTIVE TARGETING OF MAGNETIC ALBUMIN MICROSPHERES CONTAINING DOXORUBICIN
TUMOR REMISSION IN YOSHIDA SARCOMA-BEARING RATS BY SELECTIVE TARGETING OF MAGNETIC ALBUMIN MICROSPHERES CONTAINING DOXORUBICIN
复制标题
DOI：
10.1073/pnas.78.1.579
复制
发表时间：
1981-01-01
期刊：
影响因子：
--
通讯作者：
SENYEI, AE
中科院分区：
文献类型：
--
作者：
WIDDER, KJ;MORRIS, RM;SENYEI, AE
利用体外磁铁选择性靶向[大鼠]吉田肉瘤肿瘤细胞，研究了含有阿霉素和磁铁矿（Fe3O4）的磁响应白蛋白微球。将肿瘤细胞接种于大鼠尾部；肿瘤开始治疗。将含药微球（每公斤体重0.5 mg阿霉素）通过尾侧腹动脉注入肿瘤附近，同时将肿瘤暴露在5500 Oe （Oersted）的外部磁场中30分钟。对照动物接受阿霉素自由静脉注射（5mg /kg）或动脉内输注（5mg /kg和0.5 mg/kg），动脉内输注含药微球（0.5 mg/kg），不使用外磁铁或安慰剂微球进行磁定位。在实验组的12只动物中，有9只表现出肿瘤的完全缓解，肿瘤的长度达到了60mm。其余3只大鼠肿瘤消退明显；实验组无死亡或转移发生。在所有对照组中，肿瘤大小显著增加，并发生广泛转移；大多数老鼠死亡。利用磁性微球将溶瘤药物靶向实体肿瘤可能是提高抗肿瘤药物疗效和降低其毒性的一种手段。
Magnetically responsive albumin microspheres containing doxorubicin and magnetite (Fe3O4) were selectively targeted to [rat] Yoshida sarcoma tumor cells in rats by utilizing an extracorporeal magnet. Tumor cells were incoinoculated s.c. in the tail of rats; the tumors initiating treatment. Drug-bearing microspheres (0.5 mg of doxorubicin per kg of body weight) were infused approximal to the tumor through the ventral caudal artery while the tumor was exposed to an external magnetic field of 5500 Oe (Oersted] for 30 min. Control animals received free doxorubicin administered i.v. (5 mg/kg) or infused intraarterially (5 and 0.5 mg/kg), drug-bearing microspheres infused intraarterially (0.5 mg/kg) without the external magnet or placebo microspheres with magnetic localization. Of the 12 animals treated with a single dose in the experimental group, 9 exhibited total remission of the tumor, representing a disappearance of tumors as large as 60 mm in length. Marked tumor regression was observed in the remaining 3 rats; no deaths or metastases occurred in the experimental group. Significant increases in tumor size with widespread metastases occurred in all control groups; most rats died. Targeting of oncolytic agents to solid neoplasms by magnetic microspheres may be a means of increasing the efficacy and decreasing the toxicity of antitumor agents.